click enter text
leg sign
merck report financi result thursday compani
came broadli in-lin revenu beat ep narrow revenu
guidanc rais non-gaap ep guidanc addit rais
quarterli dividend announc new share
repurchas author includ asr keytruda in-
line gardasil big beat lend support recent thesi
growth opportun product under-appreci aspect stori
bodi report full analysi
addit detail us/eu drug
compani cover see recent initi report oct
trade fundament data
upsid target
factset/wolf research price oct
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
thursday open merck
report result came broadli in-lin consensu revenu beat ep
announc would increas quarterli dividend
post solid gardasil confirm recent thesi growth opportun product may
overal impress solid quarter overal dividend increas acceler buy-back program
appreci quit question mrk busi develop plan driven said part
prepar remark see seem suggest routin bolt-on
industri normal pursu provid much addit color howev gener tend disclos
less question composit payer channel mix exampl ask
quantifi certain opportun normal compani better use
recent re-initi outperform rate construct view think two
under-appreci aspect stori long-term adjuv io opportun someth would
benefit seller anti-pdx therapi gardasil often view sleepi product
global demand could see substanti long-term acceler messag chang hpv-
cancer-prev vaccin given femal male
term sale ep exhibit
revenu report sale vs consensu estim
ep report non-gaap ep vs consensu estim
keytruda sale vs estim consensu anoth solid quarter io
januvia/janumet sale vs estim consensu
gardasil sale vs estim consensu big quarter y/i
comparison goos due cdc stockpil borrow also due higher organ demand
eu on-going launch china
rais narrow financi guidanc exhibit
page
revenu narrow guidanc vs prior mid-point
ep rais guidanc vs prior mid-point
pipelin materi new news disclos
revenu increas ep increas
revenu estim increas ep estim increas
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate increas repres peer
gener prepar remark note
vote confid futur note big increas dividend along new
acceler share buy-back program even say busi develop remain major
spend capit project satisfi higher-than-previously-
expect demand variou product
eu lung repres major sale major market
 view renal data vs competitor like opdivo yervoy remind top-lin
data came first interim analysi hit os suggest strong
efficaci set efficaci extrem import enthusiast answer
question regimen vs competitor
 regard renal see meaning opportun improv efficaci well combo
agent like lenvima say tki slightli differ characterist excit
lenvima partli prior endometri result
page
 neoadjuv adjuv tnbc updat get close dmc review happen hard
predict data look like
 view tmb light recent disclos say
influenc data lot detail continu studi close
believ implement near-term howev wolf view perspect bmi tmb push
hail mari save part like fail show much benefit
new view us compani includ continu express view tmb may still hold
valu need studi
 market share keytruda us nsclc mel hn bladder
eu lung mono make big inroad ex-u lung largest tumor type combo
tripl size elig market come lung ramp slower b/c your get previous
txed patient bolu your get natur flow patient wouldv consid
china launch success increasingli view hpv-cancer-prev vaccin
limit cervic cancer long runway growth ahead
 seem us investor may under-appreci commerci potenti gardasil
elabor public health agenc payer term broad adopt
product go sell around year alreadi big could get would unreason
think could doubl exampl note see unpreced demand significantli
base multi-ag cohort work build suppli global demand realli continu grow
outlook vari countri hard gener time remain signific opportun
see big opportun us eu china would answer big could potenti
remain broadli stabl increas volum on-going us price pressur
 sting agonist monotherapi impact seem limit mrk view earli day difficult
say far good remain enthusiast inflammatori mediat
 updat intern rank prioriti say molecul
look pretti good think may opportun
 spin anim health current view remind alway activ review
portfolio chang mind given time believ run busi well
part still view good owner busi alway consid best
option wolf view dont hold breath divis spun anytim soon spun
page
divis partli elanco start under-perform mrk anim health busi contrast
continu grow above-market
 investor view organ growth prospect anim health say reflect
futur perform fluctuat quarter quarter continu view above-
 expand view futur margin expans inde expect meaning
expans time term specif quantif time want
 outlook bright feel busi develop actual necessari
pleas current busi especi oncolog alway need build portfolio
pipelin continu look alway need add pipelin drive futur growth
 concern drug price influenc think bd opportun believ
product make differ still demand good commerci potenti
 consensu alreadi anticip margin expans suggest low would
answer question
 ken stay longer ceo impact strategi transform deal anim health
etc remain focus whatev take deliv sharehold valu mention busi
develop option say flexibl sort deal type simpli put
chang mrk fundament analysi creat valu
 mention step-up capit spend partli build addit manufactur capac
suggest could suppli constraint complex product like gardasil look forward
next year said make necessari invest keep demand
signal suppli limit
 think us price reform say lot talk need wait see
realli get implement feel access need address wolf view continu think
small tweak made variou program net impact big mnc slight least
time also continu believ rhetor realiti often line come
talk us reform
 part sale sale channel would answer question
page
exhibit show compani report actual result vs estim consensu
exhibit merck result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit merck guidanc vs wr estim old new
page
oldnewoldnewtot slightli fx minim fx margin lower year-over-year approx bpsoper expens higher low- mid-sd fx fx adjust base due chang pension accountingp guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement pharma anim oper incom income/ expens incom outstand margin total margin incom oper
page
product revenu daili total isentress remicad simponi zepati biosimilar viral vaccin proquad varivax pneumovax comvax pedvaxhib gardasil januvia dulera allergi women bridion keytruda onc pain product earli phase revenu incl lynparza total
exhibit wr merck balanc sheet cash flow statement
page
